Skip to contentO
Oncotelic Therapeutics, Inc.
O
OTLCOncotelic Therapeutics, Inc. Q4 2014 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$2.64M-$2.64MderivedN/M vs Q4 2013 EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$2,645,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oncotelic Therapeutics, Inc. · CIK 908259 · Engraved from SEC EDGAR
Operating Cash Flowderived-$2,846,000N/M ended Dec 31, 2014 · filed Mar 30, 2015 · 89 d after period end